SAGE Journals Publishes New Data Revealing NEXGEL’s

 Patients Treated with SilverSeal Experienced Significantly Less Scarring and Improved Skin Functionality Following Surgical Incision

LANGHORNE, Pa., Oct. 03, 2022 (GLOBE NEWSWIRE) — NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that SAGE Journals’ Scars, Burns and Healing publication, a peer-reviewed journal that focuses on scar and burns research, has published new data from a study evaluating the impact of NEXGEL’s SilverSeal^® hydrogel dressing on postoperative scarring and complications. The results demonstrated significant scar improvement in patients treated with SilverSeal.

Study Design:

• SilverSeal was used post-surgery as an antimicrobial dressing to evaluate its ability to aid in the healing process.
• 40 foot and ankle patients (aged 32 to 66) were included in the double-blind, randomized study with 20 patients in each group.
• Postoperatively, the treatment group was given a SilverSeal hydrogel dressing, and the control group was treated with a standard petroleum-based dressing.
• Scarring and complications were evaluated, and follow-up was performed at two, six and 12 weeks post-surgery using the Patient and Observer Scar Assessment Scale (POSAS), which measures a scar’s quality from both the physician and patient’s perspective.
• Patients were not excluded in the study based on gender, age or comorbidity.

 Results:

• The treatment group demonstrated statistically significant improvements in the POSAS observer score and observer opinion at six and 12 weeks (p<0.001).
• Patients in the treatment group reported significantly reduced pain, compared with the control group, at 12 weeks (p<0.001).
• Patients reported that itching at the surgical site declined over time for both groups (p<0.001), with significantly less itching reported by the treatment group (p=0.027).
• The scar area considerably…